EN DE
Watch Palatin Technologies, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Palatin Technologies, Inc (PTN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Palatin Technologies, Inc stock $3.02, price $6.27, that is 51.9% below the price, quality 60 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PT Palatin Technologies, Inc logo Thin data Nov 8, 2026

Palatin Technologies, Inc

PTN · US
Solid, but very expensive

Our calculation puts a fair price 52% below what the stock costs today.

Quality 60/100
Low debt
Mixed Growth (revenue 3y +39.5 %/yr in USD)
Revenue last quarter 80% below a year ago.
Fair value $3.02 · Strongly overvalued
Loss-making · -63.5% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 9/100
Thin data
⚠ Dilution
Watch Palatin Technologies, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1,069 $4.10 Fair Value $3.02 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $4.10 – $1,069 · fair‑value band $1.99 – $3.77 · the $6.27 price screens above the $3.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Palatin Technologies in your weekly email

Every Wednesday you see whether Palatin Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.

Show moreShow less

It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.

The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Stock analysis

Palatin Technologies, Inc (PTN) currently trades at $6.27, while our model-based Fair Value estimate is $3.02, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.99 (bear) to $3.77 (bull), the price of $6.27 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Palatin Technologies, Inc reported revenue of $13.2M in FY2026 versus $1.5M in FY2022, a compound +73.1%/yr. Reported net income was −$8.4M in FY2026.

Key figures

Market cap $13.2M Micro · P/S ratio 1.00 · EPS (TTM) $−2.66 · Net margin −63.5% · Return on equity −878% · Return on assets (EBIT) −226% (5-year average) · Operating margin −1,470% · Revenue (TTM) $13.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 78% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −52%, PTN screens richer than that median.

Fair Value models

Bear $1.99 Fair Value $3.02 Bull $3.77
Price $6.27 · Downside -51.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $2.34 $3.55 $4.44 54
All 1 models by family
Asset-Based
NCAV (Graham) $2.34 $3.55 $4.44 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 18
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleStephen T WillsExecutive VP and CFO/COO565 shares at $16.74$9,458Dec 24, 202510b5-1 plan

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.5%
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−20,007.6% (2020) → −65.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

PTN screens overvalued: fair value 52% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Palatin Technologies, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 60 · Top 25%
Fair Value upside −51.9% · Below median
Profitability
Return on assets −98.3% · Bottom 25%
Net margin (12 months) −63.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −80.1% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.98× · Pricier than median
P/S (12 months) 1.00× · Cheapest 25%
PEG 1.62× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs PTN
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs PTN
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs PTN
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs PTN
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs PTN
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs PTN
argenx SE ARGX $927.21 $908.40 −2% vs PTN
CSL Limited CSL A$200.77 A$183.04 −9% vs PTN
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs PTN
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs PTN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Palatin Technologies, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Palatin Technologies, Inc Fair Value". https://www.fairvalue-calculator.com/stock/PTN

Frequently asked questions

Is Palatin Technologies, Inc (PTN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $3.02 versus a price of $6.27, about 52% lower (overvalued).
What is the fair value of PTN?
Our model-based fair value for Palatin Technologies, Inc is $3.02 (as of Nov 8, 2026), built from audited fundamentals. The current price: $6.27.
What is the quality score of PTN?
Palatin Technologies, Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Palatin Technologies, Inc (PTN)?
Our model-based price target is the fair value of $3.02 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $1.99, optimistic scenario $3.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Palatin Technologies, Inc stock forecast for 2026?
Our models put fair value at $3.02, about 52% lower versus a price of $6.27 (overvalued). Cautious scenario $1.99, optimistic scenario $3.77. The calculation is refreshed regularly with new filings.
What is the revenue of Palatin Technologies, Inc (PTN)?
Palatin Technologies, Inc reported trailing-twelve-month revenue of about $13.2M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Palatin Technologies, Inc (PTN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Palatin Technologies, Inc it is $3.02 per share (as of Nov 8, 2026), against a price of $6.27. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Palatin Technologies, Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, PTN trades above its calculated fair value: price $6.27, fair value $3.02, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTN?
No. The price is what the market pays today ($6.27); the fair value is what the company's own numbers justify ($3.02). For Palatin Technologies, Inc the two are $3.25 per share apart. That gap is exactly why we show both numbers side by side.
How much is Palatin Technologies, Inc worth?
The market values Palatin Technologies, Inc at about $13.2M (market capitalisation, as of Nov 8, 2026). Per share that is $6.27; our models calculate a fair value of $3.02 per share.
What do the bullish and bearish scenarios say about PTN?
Our models span a range for Palatin Technologies, Inc: cautious scenario $1.99, base $3.02, optimistic $3.77 per share (as of Nov 8, 2026, price $6.27). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of PTN?
The PEG ratio of Palatin Technologies, Inc is 1.62 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How far is PTN from its 52-week high?
Palatin Technologies, Inc trades at $6.27, about 78% below its 52-week high of $28.00 and 31% above the low of $4.77 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.02 is for.
Which stocks are comparable to Palatin Technologies, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Palatin Technologies, Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $6.27, calculated fair value $3.02 (−52%), Quality Score 60/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PTN calculated?
We run Palatin Technologies, Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $3.02 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Palatin Technologies, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Palatin Technologies, Inc (PTN)?
The closing price on Nov 6, 2026 was $6.27. Our model-based fair value is $3.02, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Palatin Technologies, Inc right now?
The price sits above even our optimistic bull case ($3.77). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($1.99 to $3.77) leaves room in how you read the outcome.

Key figures of Palatin Technologies, Inc

How large is the market capitalisation of Palatin Technologies, Inc (PTN)?
The market capitalisation of Palatin Technologies, Inc is $13.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Palatin Technologies, Inc (PTN)?
The price-to-sales ratio of Palatin Technologies, Inc is 1.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Palatin Technologies, Inc (PTN)?
Earnings per share at Palatin Technologies, Inc are $−2.66. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Palatin Technologies, Inc (PTN)?
The net margin of Palatin Technologies, Inc is −63.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Palatin Technologies, Inc (PTN)?
The return on equity (ROE) of Palatin Technologies, Inc is −878% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Palatin Technologies, Inc (PTN)?
On an EBIT basis the return on assets of Palatin Technologies, Inc is −226% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Palatin Technologies, Inc (PTN)?
The operating margin of Palatin Technologies, Inc is −1,470% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Palatin Technologies, Inc (PTN)?
Revenue at Palatin Technologies, Inc is growing −80.1% versus a year earlier (3y avg +39.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Palatin Technologies, Inc (PTN) generate?
The free cash flow of Palatin Technologies, Inc is −$13.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Palatin Technologies, Inc (PTN) hold?
Palatin Technologies, Inc holds more cash than debt, $7.3M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Palatin Technologies, Inc in the live analysis

One click puts Palatin Technologies, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.